STOCK TITAN
  1. Home
  2. News
  3. CALC

CALCIMEDICA INC - CALC STOCK NEWS

Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.

CalciMedica Inc (CALC) is a clinical-stage biopharmaceutical company advancing novel therapies targeting calcium release-activated calcium (CRAC) channels for severe inflammatory conditions. This page provides centralized access to official news and developments regarding their innovative pipeline.

Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and scientific advancements. Key focus areas include acute pancreatitis, kidney injury, and pediatric pancreatic toxicity treatments currently in Phase 2 trials.

The resource features verified information on Auxora™ clinical data, partnership announcements, and research publications. Content is rigorously curated to support informed analysis while maintaining compliance with financial disclosure standards.

Bookmark this page for direct access to CALC's latest press releases and objective updates on their CRAC channel inhibition therapies. Check regularly for developments in this specialized area of immunomodulation research.

News

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Rhea-AI Summary
CalciMedica, Inc. announces the clearance of its IND application by the FDA for its lead product candidate, Auxora, to be evaluated in a Phase 2 trial for acute kidney injury with associated acute hypoxemic respiratory failure. The trial, named KOURAGE, aims to address the high mortality rate of patients suffering from severe AKI, a condition with no approved therapies. The study will evaluate 150 patients with stage 2 and 3 AKI and AHRF, with primary endpoints focusing on days alive, ventilator-free, and dialysis-free through day 30. The development of Auxora is supported by clinical and pre-clinical evidence, showing promising results in animal models of AKI and COVID-19 pneumonia patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.21%
Tags
clinical trial
-
News

CalciMedica to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Rhea-AI Summary
CalciMedica Inc. announced the participation of CEO Rachel Leheny in the Oppenheimer 34th Annual Healthcare Life Sciences Conference. The company is focused on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. The presentation will be available via live webcast and archived for 90 days on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.99%
Tags
conferences
-
News

CalciMedica Announces Private Placement of up to Approximately $55 Million

Rhea-AI Summary
CalciMedica, Inc. announced a securities purchase agreement to raise up to $55 million in gross proceeds, with an upfront funding of $20.4 million and potential additional funding of $34.2 million. The financing will support the expansion of Auxora™ clinical development, including planned Phase 2 acute kidney injury (AKI) trial, and fund subsequent clinical trials in acute pancreatitis (AP) and AKI programs. New and existing investors, including healthcare-dedicated investors, are participating in the financing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.09%
Tags
none
News

CalciMedica Collaborator St. Jude Children's Research Hospital Presents Data from Initial Cohort of CRSPA Study at 65th Annual ASH Meeting & Exposition

Rhea-AI Summary
CalciMedica Inc. (CALC) announced positive results from the Phase 1/2 CRSPA study of Auxora™ in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) at the 65th Annual American Society of Hematology (ASH) Meeting & Exposition. Auxora treatment potentially reduces the severity of AIPT, eliminating the need for total parenteral nutrition, and resulting in reduced hospital and intensive care unit days. The study showed a 53% reduction in days in hospital and a 40% reduction in intensive care unit days compared to a historical matched control group. None of the Auxora-treated patients had significant necrosis compared to 27% of historical control patients at 30 days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.88%
Tags
none
-
News

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Rhea-AI Summary
CalciMedica Inc. (CALC) reported financial results and clinical updates for the third quarter, highlighting the expansion of Phase 1/2 CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) and the international expansion of Phase 2b CARPO trial in acute pancreatitis (AP) patients with accompanying systemic inflammatory response syndrome (SIRS). The company anticipates topline data from the CARPO trial in the first half of 2024 and is preparing to file an IND application for Auxora™ in acute kidney injury (AKI).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.74%
Tags
earnings
-
News

CalciMedica Announces Presentation of Initial Data from the CRSPA Study of Auxora at the 65th Annual ASH Meeting & Exposition

Rhea-AI Summary
CalciMedica Inc. announced the presentation of data from the CRSPA study of Auxora™ in asparaginase-induced pancreatic toxicity (AIPT) at the ASH Meeting. The results showed a 53% reduction in hospital days, a 40% reduction in ICU days, and eliminated the need for total parenteral nutrition (TPN).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.23%
Tags
none
News

CalciMedica Announces Upcoming Presentations and Events in September

Rhea-AI Summary
CalciMedica to participate in H.C. Wainwright conference and host virtual Acute Pancreatitis event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.18%
Tags
conferences
-
News

CalciMedica to Host Acute Pancreatitis Clinical Experts Event on September 21, 2023

Rhea-AI Summary
CalciMedica to host virtual clinical experts event on September 21, 2023, discussing lead clinical compound Auxora™ and its potential implications in acute pancreatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
conferences
-
News

CalciMedica Reports Second Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Rhea-AI Summary
CalciMedica reports financial results for Q2 2023 and provides updates on clinical trials and key leadership appointments
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
earnings
News

CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP)

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.07%
Tags
none
Stock CALC logo
CALCIMEDICA INC

Nasdaq:CALC

CALC Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CALC Stock Data

20.90M
11.10M
17.6%
52.45%
0.72%
Biotechnology
Pharmaceutical Preparations
Link
United States
LA JOLLA